. Features of randomized, double-blind, multinational studies in patients with early Parkinson's disease Parameter ADAGIO [28] TEMPO [25, 26] ES RAS 1 mg/d (n = 
Inclusion criteria
Age 30-80 [28] or >35 [25, 26] y; not currently receiving therapy for PD; [28] ‡2 of the 3 cardinal features of PD [25, 26] (bradykinesia, resting tremor b or rigidity); [28] HY stage £3 [25, 26] 
Selected exclusion criteria
Atypical or secondary parkinsonism; clinically significant depression; [25, 26] disease duration >18 mo; [28] HY stage ‡3;
[28] MMSE score of £23; [25, 26] received any antiparkinsonian medication for >3 wk; [28] received RAS or selegiline (any dose) or ubidecarenone (coenzyme Q) [>300 mg/d] within the previous 120 d; [28] unstable medical problems [25, 26] 
Concomitant medication
No antiparkinsonian medication [28] (except cholinergic receptor antagonists), [25, 26] antidepressant therapies (exceptions not specified [28] or amitriptyline, fluvoxamine, paroxetine, sertraline or trazodone [25, 26] ) or sympathomimetics [25, 26] permitted; no dietary tyramine restrictions [28] Primary endpoint(s) See table IV Change from baseline to wk 26 [25] and 52 [26] in the total UPDRS score c a Total UPDRS scores range from 0 to 176, UPDRS ADL subscale scores range from 0 to 52, UPDRS mental function and motor function subscale scores range from 0 to 108, and HY stages range from 1 to 5; higher scores indicate more severe PD. [28] b Patients were required to experience unilateral symptom onset if resting tremor was not present. [28] c The primary analysis of this endpoint was the difference between RAS 1 or 2 mg/d versus PL at wk 26 [25] and between ES RAS 1 and 2 mg/d versus DS RAS 2 mg/day at week 52 [26] in the mean change from baseline in the adjusted total UPDRS score. Page 662, column 2, section 7, paragraph 2, lines 1-4: The following sentence, which previously read:
In the EU, [10] oral rasagiline is indicated as monotherapy or as adjunctive therapy to levodopa for the treatment of idiopathic Parkinson's disease in adult patients with end-of-dose fluctuations.
has now been corrected as follows:
In the EU, [10] oral rasagiline is indicated for the treatment of idiopathic Parkinson's disease as monotherapy or as adjunctive therapy to levodopa in patients with end-of-dose fluctuations.
Note
All versions of this article have been updated to reflect these corrections.
